If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksElixirr International Regulatory News (ELIX)

Share Price Information for Elixirr International (ELIX)

Share Price is delayed by 15 minutes
Get Live Data
690.00    -6.00 (-0.86%)
Bid:
692.00
Ask:
710.00
Spread: 18.00 (2.601%)
Market Cap: £341.97m
ELIX Live PriceLast checked at - London Stock Exchange

Intraday Elixirr International Share Chart

Publication of Prospectus

24 Jun 2025 15:44

RNS Number : 2327O
Elixirr International PLC
24 June 2025
 

This announcement is an advertisement for the purposes of the Prospectus Regulation Rules of the Financial Conduct Authority and not a prospectus. This announcement does not constitute or form part of, and should not be construed as, an offer for sale or subscription of, or solicitation of any offer to subscribe for or to acquire, any ordinary shares of Elixirr International plc in any jurisdiction, including in or into or from the United States of America, Australia, Canada, Japan, the Republic of South Africa or in any other jurisdiction.

24 June 2025

ELIXIRR INTERNATIONAL PLC

Publication of Prospectus

Elixirr International plc (AIM:ELIX) ("Elixirr", the "Company" or, together with its subsidiary undertakings, the "Group"), an established, global award-winning challenger consultancy, is pleased to announce the publication of a prospectus (the "Prospectus") in relation to the proposed admission of its ordinary shares (the "Ordinary Shares") to listing on the Equity Shares (Commercial Companies) Category of the Official List of the Financial Conduct Authority (the "FCA") and to trading on the Main Market for listed securities of the London Stock Exchange (together, "Admission").

 

It is expected that: (i) Admission will take place at 8.00 a.m. on 1 July 2025; and (ii) the Ordinary Shares will be cancelled from trading on AIM at 8.00 a.m. on 1 July 2025. The last day of trading of the Ordinary Shares on AIM is therefore expected to be 30 June 2025.

 

Elixirr confirms that, to the best of its knowledge, all known and material IHT holders have now exited the Company's share register.

 

Elixirr is not offering any new Ordinary Shares nor any other securities in connection with the proposed Admission. Following Admission, the Ordinary Shares will continue to be registered with their existing ISIN of GB00BLPHTX84 and the TIDM will remain ELIX.

 

The Company's shareholders should consult their own professional advisers regarding the consequences of Admission for them.

 

The Prospectus has been approved by the FCA and will shortly be available to view on Elixirr's website, [https://www.elixirr.com/en-gb/investors]. A copy of the Prospectus will be submitted to the National Storage Mechanism and will be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

 

Enquiries:

For enquiries, please refer to the Company's Investor Contacts page:

https://www.elixirr.com/investors/investor-contacts

Elixirr International plc  +44 (0)20 7220 5410  

Stephen Newton, Chief Executive Officer

Graham Busby, Deputy Chief Executive Officer

Nick Willott, Chief Financial Officer and Company Secretary

investor-relations@elixirr.com

Cavendish Capital Markets Ltd (Nominated Adviser & Joint Broker) +44 (0)20 7220 0500

Stephen Keys, Callum Davidson, Isaac Hooper (Corporate Finance),

Sunila De Silva (ECM)

Peel Hunt LLP (Sponsor & Joint Broker)  +44 (0)20 7418 8900

Neil Patel, Ben Cryer, Alice Lane, Kate Bannatyne

 

About Elixirr International plc

Elixirr is an award-winning global consulting firm working with clients across a diverse range of industries, markets and geographies. Founded in 2009, the firm set out to be the 'challenger consultancy' and do things differently than the large corporate consultancies dominating the industry: working openly and collaboratively with clients from start to finish, delivering outcomes based on innovative thinking, not methodology, and treating each client's business like their own. Elixirr has been quoted on the AIM market of the London Stock Exchange since 2020. In addition to strong organic growth, Elixirr has acquired seven boutique firms - Den Creative, Coast Digital, The Retearn Group, iOLAP, Responsum, Insigniam and Hypothesis - to grow the Group's capabilities, diversify the business, expand into new geographies and access new clients.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
PDIPKQBQQBKDBAB
Date   Source Headline
30th Jun 20261:33 pmRNSResult of AGM
2nd Jun 20269:49 amRNSNotice of AGM and Dividend Timetable
20th May 20267:00 amRNSIssue of Equity - TRC Contingent Consideration
14th May 20268:38 amRNSHolding(s) in Company
29th Apr 20263:59 pmRNSHolding(s) in Company
29th Apr 202611:18 amRNSPublication of 2025 Annual Report
28th Apr 20265:59 pmRNSResult of Secondary Placing
28th Apr 20264:35 pmRNSProposed Secondary Placing
20th Apr 20267:00 amRNSResults for the year ended 31 December 2025
10th Apr 20267:00 amRNSHolding(s) in Company
27th Mar 20267:00 amRNSNotice of FY 25 Investor Presentation
23rd Mar 20267:00 amRNSGrant of Share Options
19th Mar 202610:09 amRNSDirector/PDMR Shareholding
27th Feb 202610:26 amRNSDirector/PDMR Shareholding
25th Feb 20267:00 amRNSDirector/PDMR Shareholding
2nd Feb 20267:00 amRNSAcquisition of Kvadrant Consulting A/S
30th Jan 20267:00 amRNSAppointment of Non-Executive Director
22nd Jan 20267:00 amRNSTrading Update and Interim Dividend
9th Jan 20264:37 pmRNSPDMR Shareholding
25th Sep 20258:08 amRNSDirector/PDMR Shareholding
22nd Sep 20257:01 amRNSInterim Results
22nd Sep 20257:00 amRNSAcquisition of TRC Advisory, LLC
18th Sep 20253:28 pmRNSIncrease in Debt Facilities to Support M&A
17th Sep 20257:00 amRNSNotice of H1 25 Investor Presentation
15th Sep 20257:00 amRNSMove from SETSqx to SETS
14th Jul 20257:00 amRNSTrading Update
10th Jul 20257:00 amRNSChange of Adviser
1st Jul 20258:00 amRNSReadmission - Elixirr International Plc
1st Jul 20257:00 amRNSAdmission to Main Market
26th Jun 20256:00 pmRNSElixirr International
24th Jun 20253:44 pmRNSPublication of Prospectus
24th Jun 202512:39 pmRNSResult of AGM
10th Jun 20257:00 amRNSGrant of Share Options
30th May 20257:00 amRNSMain Market Update & Capital Markets Day
29th May 20253:58 pmRNSPDMR Dealings and EBT Transfers
29th May 20257:00 amRNSPosting of Annual Report and Accounts
21st May 20257:00 amRNSCapital Markets Day
8th May 202512:21 pmRNSHoldings in Company – Employee Benefit Trust
28th Apr 20257:00 amRNSFinal Results
11th Mar 20257:00 amRNSNotice of FY24 Investor Presentation
18th Feb 20257:00 amRNSTrading Update
22nd Jan 20257:00 amRNSGrant of Restricted Share Awards
17th Jan 20251:40 pmRNSPurchase of Shares by Employee Benefit Trust
16th Jan 20253:05 pmRNSDirector/PDMR Shareholding
13th Jan 20258:06 amRNSBoard Appointment
6th Jan 20257:00 amRNSAppointment of Joint Broker
20th Dec 20244:20 pmRNSDirector/PDMR Shareholding
20th Dec 20247:00 amRNSInterim Dividend
10th Dec 20247:00 amRNSBoard Changes
25th Nov 20247:00 amRNSChange of Adviser

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.